Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.06 +2.43 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
65 66 Next >
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030. 
Via Benzinga
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Apple Inc. is a "buy" after iPhone sales in China saw a 52% year-on-year increase. 
Via Benzinga
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to... 
Via Benzinga
Where Will Novo Nordisk Be in 10 Years?
Will Novo Nordisk top $1 trillion in market value? 
Via The Motley Fool
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. 
Via The Motley Fool
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates and fees. 
Via Benzinga
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
Ozempic Maker Novo Nordisk's Increasing Influence On Denmark's Employment Raises Economic Concerns
The updated employment figures have heightened concerns about Denmark's economy becoming excessively dependent on Novo. 
Via Benzinga
Topics Economy
Exposures Economy
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights. 
Via The Motley Fool
The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop
Overlooked penny stocks are the path to outsized gains and these shares seem to fit the bill at the moment. 
Via InvestorPlace
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola. 
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first. 
Via Benzinga
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
The gold rush for obesity medications just got a bit more intense. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
Elon Musk predicts that Novo Nordisk's weight-loss drug Ozempic will eventually become very cheap, following its depiction in a new South Park special as a luxury medication accessible only to the... 
Via Benzinga
Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression
Novo Nordisk's Ozempic was used on 3,533 patients; results show a 24% reduction in kidney disease progression. 
Via Benzinga
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Most Dow stocks are strong investments but these 7 stand out at the moment as the macroenvironment trends positive again. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders. 
Via InvestorPlace
Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in... 
Via Benzinga
Exposures Product Safety
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia. 
Via Benzinga
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide. 
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
Investors wanting to get rich should consider a long-term holding in these stocks, each of which has risen exponentially in the last year. 
Via InvestorPlace
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide. 
Via Benzinga
7 Reliable Blue-Chip Stocks That Cannot Miss
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now. 
Via InvestorPlace
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.